Prevalence of Olfactory Dysfunction in Coronavirus Disease 2019 (COVID-19): A Meta-analysis of 27,492 Patients
Prevalence of Olfactory Dysfunction in Coronavirus Disease 2019 (COVID-19): A Meta-analysis of 27,492 Patients
复制标题
DOI：
10.1002/lary.29286
复制
发表时间：
2020-12-05
期刊：
影响因子：
2.6
通讯作者：
Abdullah, Baharudin
中科院分区：
文献类型：
--
作者：
Saniasiaya, Jeyasakthy;Islam, Md Asiful;Abdullah, Baharudin
目的/假设嗅觉功能障碍已被观察到作为COVID-19患者的临床表现之一。研究设计系统性综述和荟萃分析方法检索PubMed、Scopus、Web of Science、Embase和Google Scholar数据库，以确定2019年12月1日至2020年7月23日期间发表的研究。我们使用随机效应模型估计合并患病率的95%置信区间（CI）。使用I-2统计量和Cochran's Q检验来评估异质性。该研究在PROSPERO注册（CRD 42020183768）。结果共纳入1162篇研究，其中83篇研究（n = 27492，女性占61.4%）纳入荟萃分析。总体而言，COVID-19患者嗅觉功能障碍的汇总患病率为47.85% [95%CI：41.20-54.50]。我们在54.40%的欧洲患者、51.11%的北美患者、31.39%的亚洲患者和10.71%的澳大利亚COVID-19患者中观察到嗅觉功能障碍。嗅觉丧失、嗅觉减退和嗅觉障碍分别占35.39%、36.15%和2.53%。客观（患病率较高）与主观（患病率较低）评价的研究结果存在差异。这种差异可能是由于在自我报告的健康措施中观察到的假阴性报告。结论基于高质量证据，COVID-19患者嗅觉功能障碍的患病率为47. 85%。由于大多数研究的主观指标在分析中汇总，因此主张进一步研究客观指标以证实这一发现。证据等级2喉镜，2020
Objectives/Hypothesis Olfactory dysfunction has been observed as one of the clinical manifestations in COVID-19 patients. We aimed to conduct a systematic review and meta-analysis to estimate the overall pooled prevalence of olfactory dysfunction in COVID-19 patients.Study Design Systematic review and meta-analyses.Methods PubMed, Scopus, Web of Science, Embase, and Google Scholar databases were searched to identify studies published between 1 December 2019 and 23 July 2020. We used random-effects model to estimate the pooled prevalence with 95% confidence intervals (CIs). Heterogeneity was assessed using the I-2 statistic and Cochran's Q test. Robustness of the pooled estimates was checked by different subgroup and sensitivity analyses This study is registered with PROSPERO (CRD42020183768).Results We identified 1162 studies, of which 83 studies (n = 27492, 61.4% female) were included in the meta-analysis. Overall, the pooled prevalence of olfactory dysfunction in COVID-19 patients was 47.85% [95% CI: 41.20-54.50]. We observed olfactory dysfunction in 54.40% European, 51.11% North American, 31.39% Asian, and 10.71% Australian COVID-19 patients. Anosmia, hyposmia, and dysosmia were observed in 35.39%, 36.15%, and 2.53% of the patients, respectively. There were discrepancies in the results of studies with objective (higher prevalence) versus subjective (lower prevalence) evaluations. The discrepancy might be due to false-negative reporting observed in self-reported health measures.Conclusions The prevalence of olfactory dysfunction in COVID-19 patients was found to be 47.85% based on high-quality evidence. Due to the subjective measures of most studies pooled in the analysis, further studies with objective measures are advocated to confirm the finding.Level of Evidence 2 Laryngoscope, 2020